Navigating the Landscape of Uterine Fibroid Treatment Using a Novel Scarless Technology (GYIDE): A Case Report.

Gynecol Minim Invasive Ther

Department of Research and Development, Nesa Medtech Pvt. Ltd., Bengaluru, Karnataka, India.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Uterine fibroids (UFs) affect 70%-80% of women by age 50. Traditional treatments include medical management and invasive surgery. Recent advancements in fibroid treatment introduce less invasive methods like radiofrequency ablation (RFA), microwave ablation, uterine artery embolization, and MR-guided focused ultrasound. Accurate fibroid mapping and electrode placement are major challenges in the case of fibroid ablation. GYIDE, a scarless technology, demonstrates the feasibility for ultrasound-guided transcervical RFA. A 40-year-old woman with multiple intramural fibroids underwent RFA using GYIDE prior to hysterectomy. The procedure involved preoperative ultrasound, three-dimensional fibroid rendering, real-time mapping, and delivering the RFA for UF. Transcervical RFA targeted a 4 cm × 3.5 cm fibroid at 115 W for 5 min under ultrasound guidance. The GYIDE system enabled safe, precise RFA without complications. Intraoperative ultrasound confirmed effective ablation. Postthysterectomy analysis revealed no serosal perforation or thermal damage. The 4 mm navigation arm avoided cervical dilation, reducing discomfort. GYIDE delivers safe and precise transcervical RFA for UFs, with promising potential for expanded applications with advancing research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334091PMC
http://dx.doi.org/10.4103/gmit.GMIT-D-25-00043DOI Listing

Publication Analysis

Top Keywords

transcervical rfa
12
fibroid treatment
8
scarless technology
8
safe precise
8
rfa
7
fibroid
6
gyide
5
navigating landscape
4
landscape uterine
4
uterine fibroid
4

Similar Publications

Uterine fibroids (leiomyomas) and adenomyosis are among the most common benign gynecological conditions affecting women of reproductive age. These disorders are frequently associated with abnormal uterine bleeding, pelvic pain, pressure symptoms on adjacent pelvic organs, and potential infertility. The incidence of fibroids increases as women enter their third and fourth decades of life.

View Article and Find Full Text PDF

Navigating the Landscape of Uterine Fibroid Treatment Using a Novel Scarless Technology (GYIDE): A Case Report.

Gynecol Minim Invasive Ther

July 2025

Department of Research and Development, Nesa Medtech Pvt. Ltd., Bengaluru, Karnataka, India.

Uterine fibroids (UFs) affect 70%-80% of women by age 50. Traditional treatments include medical management and invasive surgery. Recent advancements in fibroid treatment introduce less invasive methods like radiofrequency ablation (RFA), microwave ablation, uterine artery embolization, and MR-guided focused ultrasound.

View Article and Find Full Text PDF

Objective: To evaluate the incidence of and risk factors for major complications and surgical reintervention following transcervical ultrasound-guided radiofrequency ablation (RFA) of uterine fibroids.

Methods: In this retrospective study, 1290 patients with 1358 symptomatic uterine fibroids underwent outpatient transcervical ultrasound-guided RFA between July 2009 and July 2021. Medical records were reviewed to assess major complications and surgical reintervention rates.

View Article and Find Full Text PDF

Radiofrequency ablation (RFA) is a relatively novel, increasingly popular treatment option for leiomyomas. We studied medical device-related reports of leiomyoma RFA devices to determine whether there are emerging device-related issues. The Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) database was queried from 2012 through November 2022.

View Article and Find Full Text PDF

Radiofrequency Ablation of Leiomyomas.

Obstet Gynecol

June 2023

Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota; the Division of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts; the Department of Obstetrics and Gynecology, Division of Gynecology, University of Texas Southwes

Radiofrequency ablation (RFA) of leiomyomas represents a significant advancement in the treatment of this common uterine condition. In the appropriately selected patient, both laparoscopic and transcervical options provide effective treatment for bleeding and bulk symptoms in a uterine-sparing manner. Compared with other minimally invasive leiomyoma treatment options, RFA procedures have comparable or favorable safety profiles, recovery timelines, and reintervention rates.

View Article and Find Full Text PDF